Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE vs DELTALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
FDA: topical treatment of plaque psoriasis in patients 12 years and older,Off-label: scalp psoriasis, nail psoriasis, parapsoriasis
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
Calcipotriene: not applicable due to minimal systemic exposure. Betamethasone dipropionate: terminal half-life of betamethasone after topical application is approximately 5-6 hours.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Calcipotriene: hepatic metabolism via CYP24A1 and other enzymes; betamethasone dipropionate: mainly hepatic metabolism via CYP3A4 to various inactive metabolites.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Calcipotriene: negligible systemic absorption; absorbed fraction undergoes hepatic metabolism and is excreted in feces (approx. 70%) and urine (approx. 20%). Betamethasone dipropionate: absorbed dose metabolized in liver, metabolites excreted primarily in urine (60-70%) and feces (20-30%).
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Calcipotriene: >90% bound to plasma proteins (albumin). Betamethasone dipropionate: >90% bound to albumin.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
Calcipotriene: not clinically relevant due to low systemic absorption. Betamethasone dipropionate: Vd of betamethasone is approximately 1.4 L/kg, indicating wide distribution.
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Topical: systemic bioavailability of calcipotriene is <1% of applied dose; betamethasone dipropionate is <10% of applied dose through intact skin, but increases with inflamed skin.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Safety and efficacy in pediatric patients (age <12 years) have not been established. For patients 12–17 years, dosing is same as adult; maximum weekly dose not to exceed 60 g per week.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
No specific dose adjustment required; however, caution due to potential for increased skin atrophy, impaired renal/hepatic function, and concurrent medications. Use minimal effective amount.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA boxed warning.
None.
May cause hypercalcemia due to calcipotriene absorption, especially when applied to large areas or occluded skin,Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression from betamethasone, particularly with prolonged use, high potency, or large surface area,Local adverse reactions: skin atrophy, striae, telangiectasias, folliculitis, perioral dermatitis, allergic contact dermatitis,Not for use on face, groin, or axillae due to increased systemic absorption and skin atrophy risk,Caution in patients with renal impairment or hepatic impairment due to metabolic and excretory pathways,Do not use with occlusive dressings unless directed,May mask signs of infection and suppress immune response
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any components,Patients with known hypercalcemia or vitamin D toxicity,Active infections of skin (viral, fungal, bacterial) at treatment site,Concurrent use of other vitamin D analogues topically,Severe renal or hepatic impairment (relative)
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
No clinically significant food-drug interactions. However, maintain adequate calcium and vitamin D intake as part of a balanced diet, but avoid excessive calcium supplementation due to potential hypercalcemia risk with extensive use.
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause cleft palate, intrauterine growth restriction, and adrenal suppression in animal studies; human risk with topical use is low due to minimal systemic absorption. Avoid large areas or prolonged use in pregnancy. First trimester: theoretical risk but limited data. Second/third trimesters: low risk if used sparingly.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
Not known if excreted in human milk. Calcipotriene is likely excreted due to low molecular weight; betamethasone may appear in milk. M/P ratio not available. Use caution; apply smallest amount to smallest area, avoid breast area. Consider benefits vs risks.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
No formal dose adjustment guidelines. Use minimum effective dose for shortest duration. Avoid occlusion, extensive areas, or prolonged treatment. Monitor for local and systemic adverse effects.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
Avoid use on face, groin, axillae, or in intertriginous areas due to increased risk of corticosteroid side effects. Apply only to affected plaques; limit total weekly dose to ≤100 g or 60 m L to minimize risk of HPA axis suppression. Discontinue if skin atrophy, telangiectasias, or striae develop. Monitor for hypercalcemia in patients with extensive plaque psoriasis due to calcipotriene absorption. For patients with moderate-to-severe plaque psoriasis, consider sequential or rotational therapy to minimize long-term corticosteroid exposure.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Apply a thin layer to psoriatic plaques once daily for up to 4 weeks as directed.,Do not use on the face, armpits, groin, or areas with skin folds.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not use occlusive dressings (e.g., bandages, wraps) over the treated area.,Inform your doctor if you develop severe skin irritation, signs of skin infection, or if psoriasis worsens.,Do not use more than the prescribed amount or for longer than recommended.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE vs DELTALIN, answered by our medical review team.
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.. DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE and DELTALIN depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is: Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).. The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE and DELTALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is classified as Category C. FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause c. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.